N
Research Areas
Biography and Research Information
OverviewAI-generated summary
Nathan L. Avaritt's research interests include investigating anti-melanoma activity through various agents and molecular mechanisms. He has explored the in vitro anti-melanoma effects of the Trametes versicolor mushroom and synthesized acryloyl pyridinone analogues with similar activity. His work also involves understanding how genetic modifications, such as CRISPR/dCas9-KRAB-mediated suppression of S100b, can restore p53-mediated apoptosis in melanoma cells. Furthermore, Avaritt's research touches upon epigenetics, examining how EZH2 loss during metabolic stress influences the restoration of MHC class I machinery in melanoma, and the role of ATF6 activation in enhancing responses to immune checkpoint blockade (ICB) therapy for melanoma.
Beyond melanoma, Avaritt has contributed to studies on the gut microbiome, specifically how C-sections impact the abundance of bile acid-modifying bacteria in mice. He has also been involved in research on sepsis, investigating the protective effects of factor XI inhibition by abelacimab in a baboon model of Staphylococcus aureus sepsis. His work utilizes quantitative mass spectrometry, as highlighted in his publication on driving technologies in this field. Avaritt's scholarship metrics include an h-index of 7, with 43 total publications and 206 total citations.
Metrics
- h-index: 7
- Publications: 45
- Citations: 207
Selected Publications
-
691 ATF6 activation promotes ICB response in melanoma (2025)
-
Anthrax toxins exacerbate sepsis-induced coagulopathy and endothelial dysfunction in a baboon model of anthrax (2025)
-
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025)
-
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)
-
Abstract 4622: Proteomic insights into anti-CTLA4 therapy resistance in metastatic melanoma: Pathway-specific biomarkers for treatment response (2025)
-
Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2025)
-
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)
-
538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024)
-
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)
-
Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Cutting-Edge Technologies Driving Quantitative Mass Spectrometry (2023)
-
Cutting-Edge Technologies Driving Quantitative Mass Spectrometry (2023)
Grants & Funding
Collaboration Network
Top Collaborators
Alan J. Tackett
University of Arkansas for Medical Sciences
22 shared publications
In database
- The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
- Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues
- EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
Showing 5 of 22 shared publications
Stephanie D. Byrum
University of Arkansas for Medical Sciences
12 shared publications
In database
- Cutting-Edge Technologies Driving Quantitative Mass Spectrometry
- Integrative Proteomics and Phosphoproteomics of Asthmatic Airways following RV Infection
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
Showing 5 of 12 shared publications
Samuel G. Mackintosh
University of Arkansas for Medical Sciences
6 shared publications
In database
- Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Showing 5 of 6 shared publications
Billie Heflin
University of Arkansas for Medical Sciences
6 shared publications
In database
- The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues
- EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
- 538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response
Showing 5 of 6 shared publications
Brian Koss
University of Arkansas for Medical Sciences
5 shared publications
In database
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
- Abstract 1892: Proteomic interrogation of the metabolic control of MHC class I antigen presentation in metastatic melanoma
- 538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response
- 691 ATF6 activation promotes ICB response in melanoma
Sanjay Adhikary
University of Arkansas for Medical Sciences
5 shared publications
In database
- Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
- Author response for "Thiazole-fused Androstenone and Ethisterone Derivatives: Potent β- and γ-Actin Cytoskeleton Inhibitors to Treat Melanoma Tumors"
- Author response for "Thiazole-fused Androstenone and Ethisterone Derivatives: Potent β- and γ-Actin Cytoskeleton Inhibitors to Treat Melanoma Tumors"
- Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
- 691 ATF6 activation promotes ICB response in melanoma
Kanishka Manna
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Prashanthi Dharanipragada
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Duah Alkam
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Charity L. Washam
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Michael S. Robeson
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Zhentao Yang
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Shirley H. Lomeli
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Gatien Moriceau
Oldham Council (GB)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Santosh Kumar Paidi
Johns Hopkins University (US)
4 shared publications
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
Similar Researchers
Based on overlapping research topics
Alan J. Tackett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Metabolomics and Mass Spectrometry Studies
Kanishka Manna
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Metabolomics and Mass Spectrometry Studies
Amit K. Tiwari
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Gut microbiota and health
lan J Tackett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Katherine Wallis
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Metabolomics and Mass Spectrometry Studies
Aaron J. Storey
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolomics and Mass Spectrometry Studies
Epigenetics and DNA Methylation